Brief: FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation To Allovir’s Posoleucel For Prevention Of Multiple Life-Threatening Infections From Six Viruses In Allogeneic Hematopoietic Cell Transplant Patients
20/04/2022 12:07
April 20 (Reuters) - Allovir Inc ALVR.O :
* FDA GRANTS REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT)
DESIGNATION TO ALLOVIR’S POSOLEUCEL FOR PREVENTION OF MULTIPLE
LIFE-THREATENING INFECTIONS FROM SIX VIRUSES IN ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANT PATIENTS
Source text for Eikon: ID:nBw9sHx98a
Further company coverage: ALVR.O
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million